AstraZeneca gets FDA breakthrough therapy label for asthma treatment

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo - Copyright Stefan Wermuth(Reuters)

By Reuters

Published on 07/09/2018 - 08:34•Updated 11/05/2024 - 03:26

Comments

(Reuters) - AstraZeneca Plc <AZN.L> said on Friday the U.S. Food and Drug Administration had granted a breakthrough therapy label for its drug to treat a type of severe asthma, potentially speeding up its development and review.

The drug, Tezepelumab, is developed by British-listed AstraZeneca and its U.S. partner Amgen Inc <AMGN.O>.